Pancreatic cancer: from state-of-the-art treatments to promising novel therapies

  title={Pancreatic cancer: from state-of-the-art treatments to promising novel therapies},
  author={Ignacio Garrido-Laguna and Maartje Hidalgo},
  journal={Nature Reviews Clinical Oncology},
Pancreatic cancer is expected to be the second deadliest malignancy in the USA by 2020. The survival rates for patients with other gastrointestinal malignancies have increased consistently during the past 30 years; unfortunately, however, the outcomes of patients with pancreatic cancer have not changed significantly. Although surgery remains the only curative treatment for pancreatic cancer, therapeutic strategies based on initial resection have not substantially improved the survival of… CONTINUE READING
Highly Cited
This paper has 118 citations. REVIEW CITATIONS


Publications citing this paper.
Showing 1-10 of 121 citations

118 Citations

Citations per Year
Semantic Scholar estimates that this publication has 118 citations based on the available data.

See our FAQ for additional information.


Publications referenced by this paper.
Showing 1-10 of 180 references

Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first‐line treatment of metastatic pancreatic cancer [abstract

  • E Van Cutsem
  • J. Clin. Oncol
  • 2015

A randomized double‐blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second‐line therapy in patients (pts) with metastatic pancreatic cancer (mPC) [abstract

  • H Hurwitz
  • J. Clin. Oncol. 32 (5s Suppl.),
  • 2014

American Society of Clinical Oncology perspective : raising the bar for clinical trials by defining clinically meaningful outcomes

  • B. Wacker
  • J . Clin . Oncol .
  • 2014